X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare ALEMBIC PHARMA with Procter & Gamble Health - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs PROCTER & GAMBLE HEALTH - Comparison Results

PROCTER & GAMBLE HEALTH 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC PHARMA PROCTER & GAMBLE HEALTH ALEMBIC PHARMA/
PROCTER & GAMBLE HEALTH
 
P/E (TTM) x 16.5 60.7 27.2% View Chart
P/BV x 3.6 10.6 33.9% View Chart
Dividend Yield % 1.1 0.3 331.4%  

Financials

 ALEMBIC PHARMA   PROCTER & GAMBLE HEALTH
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-19
PROCTER & GAMBLE HEALTH
Dec-17
ALEMBIC PHARMA/
PROCTER & GAMBLE HEALTH
5-Yr Chart
Click to enlarge
High Rs6641,358 48.9%   
Low Rs412933 44.2%   
Sales per share (Unadj.) Rs208.7665.0 31.4%  
Earnings per share (Unadj.) Rs31.056.6 54.8%  
Cash flow per share (Unadj.) Rs37.172.5 51.2%  
Dividends per share (Unadj.) Rs5.5015.00 36.7%  
Dividend yield (eoy) %1.01.3 78.0%  
Book value per share (Unadj.) Rs144.2441.7 32.6%  
Shares outstanding (eoy) m188.5216.60 1,135.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.61.7 149.7%   
Avg P/E ratio x17.420.2 85.8%  
P/CF ratio (eoy) x14.515.8 91.8%  
Price / Book Value ratio x3.72.6 143.9%  
Dividend payout %17.726.5 66.9%   
Avg Mkt Cap Rs m101,46119,011 533.7%   
No. of employees `000NA1.5 0.0%   
Total wages/salary Rs m7,4671,696 440.2%   
Avg. sales/employee Rs ThNM7,150.0-  
Avg. wages/employee Rs ThNM1,098.7-  
Avg. net profit/employee Rs ThNM608.2-  
INCOME DATA
Net Sales Rs m39,34711,040 356.4%  
Other income Rs m94240 39.1%   
Total revenues Rs m39,44111,279 349.7%   
Gross profit Rs m8,7361,376 634.8%  
Depreciation Rs m1,152264 436.5%   
Interest Rs m1840-   
Profit before tax Rs m7,4931,352 554.3%   
Minority Interest Rs m110-   
Prior Period Items Rs m-930-   
Extraordinary Inc (Exp) Rs m0170 0.0%   
Tax Rs m1,568583 269.0%   
Profit after tax Rs m5,844939 622.3%  
Gross profit margin %22.212.5 178.1%  
Effective tax rate %20.943.1 48.5%   
Net profit margin %14.98.5 174.6%  
BALANCE SHEET DATA
Current assets Rs m19,5777,523 260.2%   
Current liabilities Rs m14,8962,253 661.3%   
Net working cap to sales %11.947.7 24.9%  
Current ratio x1.33.3 39.4%  
Inventory Days Days9052 172.0%  
Debtors Days Days4541 111.8%  
Net fixed assets Rs m27,0971,240 2,185.8%   
Share capital Rs m377166 227.1%   
"Free" reserves Rs m26,8117,167 374.1%   
Net worth Rs m27,1887,333 370.8%   
Long term debt Rs m4,9930-   
Total assets Rs m47,7789,912 482.0%  
Interest coverage x41.7NM-  
Debt to equity ratio x0.20-  
Sales to assets ratio x0.81.1 73.9%   
Return on assets %12.69.5 133.2%  
Return on equity %21.512.8 167.8%  
Return on capital %23.620.8 113.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m19,4531,015 1,917.3%   
Fx outflow Rs m6,0653,043 199.3%   
Net fx Rs m13,388-2,028 -660.1%   
CASH FLOW
From Operations Rs m8,120537 1,513.2%  
From Investments Rs m-7,556-476 1,586.4%  
From Financial Activity Rs m590-220 -268.6%  
Net Cashflow Rs m1,153-160 -723.1%  

Share Holding

Indian Promoters % 74.1 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 2.9 18.2 15.9%  
FIIs % 9.1 1.0 910.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 13.9 29.1 47.8%  
Shareholders   49,328 28,591 172.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC PHARMA With:   STRIDES PHARMA SCIENCE  AJANTA PHARMA  UNICHEM LAB  DR. DATSONS LABS  ELDER PHARMA  

Compare ALEMBIC PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Yes Bank's Road Ahead(Podcast)

The stock markets witnessed selling pressure in the week gone by. Market participants remained cautious tracking tepid quarterly earnings amid weak cues.

Related Views on News

ALEMBIC PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 13, 2019 | Updated on Jun 13, 2019

Here's an analysis of the annual report of ALEMBIC PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 28.9% (Quarterly Result Update)

May 9, 2019 | Updated on May 9, 2019

For the quarter ended March 2019, ALEMBIC PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.6% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

ALEMBIC PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 21, 2018 | Updated on Dec 21, 2018

Here's an analysis of the annual report of ALEMBIC PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ALEMBIC PHARMA. Also includes updates on the valuation of ALEMBIC PHARMA.

More Views on News

Most Popular

These 3 Smallcap Stocks are Set to Make the Most of Smallcap Rebound(Profit Hunter)

Jul 9, 2019

As the sense of normalcy returns to the markets, the rebound in the quality smallcaps could be huge.

2 Stocks from Super Investor Sanjay Bakshi's Portfolio You Can Bet On...(The 5 Minute Wrapup)

Jul 12, 2019

Despite the current fear prevailing in the markets, both these stocks have the potential to deliver in 4-5 years.

After Disappointing Budget, Here's a Document that Concerns Largecap and Smallcap Investors(The 5 Minute Wrapup)

Jul 8, 2019

A new 'definition' of the stock universe that triggered the smallcap sell-off is back with the latest list...

Here's What to Do with Falling Small Cap Stocks(Profit Hunter)

Jul 10, 2019

There are some great buying opportunities in the market right now - and the small cap space is your best bet.

Budget an Icing on the Cake for This Smart Money Backed Affordable Housing Stock(The 5 Minute Wrapup)

Jul 10, 2019

Affordable housing is one of the most straightforward growth stories in India. This will help the real estate sector to come out of the slump.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Jul 19, 2019 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS